222 related articles for article (PubMed ID: 15287917)
41. Shared receptor components but distinct complexes for alpha and beta interferons.
Lewerenz M; Mogensen KE; Uzé G
J Mol Biol; 1998 Sep; 282(3):585-99. PubMed ID: 9737924
[TBL] [Abstract][Full Text] [Related]
42. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.
Agirre X; Jiménez-Velasco A; San José-Enériz E; Garate L; Bandrés E; Cordeu L; Aparicio O; Saez B; Navarro G; Vilas-Zornoza A; Pérez-Roger I; García-Foncillas J; Torres A; Heiniger A; Calasanz MJ; Fortes P; Román-Gómez J; Prósper F
Mol Cancer Res; 2008 Dec; 6(12):1830-40. PubMed ID: 19074828
[TBL] [Abstract][Full Text] [Related]
43. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
44. CD81 down-regulation on B cells is associated with the response to interferon-alpha-based treatment for chronic hepatitis C virus infection.
Chang LL; Cheng PN; Chen JS; Young KC
Antiviral Res; 2007 Jul; 75(1):43-51. PubMed ID: 17194487
[TBL] [Abstract][Full Text] [Related]
45. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection.
Morita K; Tanaka K; Saito S; Kitamura T; Kondo M; Sakaguchi T; Morimoto M; Sekihara H
J Clin Gastroenterol; 1998 Mar; 26(2):135-40. PubMed ID: 9563926
[TBL] [Abstract][Full Text] [Related]
46. Retroviral vector-mediated transfer of the interferon-alpha gene in chronic myeloid leukemia cells.
Salesse S; Moreau-Gaudry F; Pigeonnier-Lagarde V; Mazurier F; Chahine H; Ged C; de Verneuil H; Reiffers J; Mahon FX
Cancer Gene Ther; 1998; 5(6):390-400. PubMed ID: 9917094
[TBL] [Abstract][Full Text] [Related]
47. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
Shiba M; Nonomura N; Nakai Y; Nakayama M; Takayama H; Inoue H; Tsujimura A; Nishimura K; Okuyama A
Int J Urol; 2009 Apr; 16(4):356-9. PubMed ID: 19302507
[TBL] [Abstract][Full Text] [Related]
48. High expression of CD7 on CD34+ cells is not linked to deletion of derivative chromosome 9 or lack of dendritic cells in chronic myeloid leukaemia.
Fløisand Y; Normann AP; Heim S; Lund-Johansen F; Tjønnfjord GE
Scand J Clin Lab Invest; 2008; 68(2):93-8. PubMed ID: 17852828
[TBL] [Abstract][Full Text] [Related]
49. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
Hasford J; Pfirrmann M; Shepherd P; Guilhot J; Hehlmann R; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Steegmann JL; Thaler J
Haematologica; 2005 Mar; 90(3):335-40. PubMed ID: 15749665
[TBL] [Abstract][Full Text] [Related]
50. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.
Lamken P; Gavutis M; Peters I; Van der Heyden J; Uzé G; Piehler J
J Mol Biol; 2005 Jul; 350(3):476-88. PubMed ID: 15946680
[TBL] [Abstract][Full Text] [Related]
51. Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis.
Kamai T; Yanai Y; Arai K; Abe H; Yamanishi T; Kurimoto M; Yoshida K
BMC Cancer; 2007 Aug; 7():159. PubMed ID: 17697365
[TBL] [Abstract][Full Text] [Related]
52. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
53. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
[TBL] [Abstract][Full Text] [Related]
54. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
Zhang L; Zhao H; Sun A; Lu S; Liu B; Tang F; Feng Y; Zhao L; Yang R; Han ZC
Haematologica; 2004 Oct; 89(10):1199-206. PubMed ID: 15477204
[TBL] [Abstract][Full Text] [Related]
55. [Study on mismatch repair genes of chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
[TBL] [Abstract][Full Text] [Related]
56. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
57. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
Nagano H; Miyamoto A; Wada H; Ota H; Marubashi S; Takeda Y; Dono K; Umeshita K; Sakon M; Monden M
Cancer; 2007 Dec; 110(11):2493-501. PubMed ID: 17941012
[TBL] [Abstract][Full Text] [Related]
58. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.
Arduini RM; Strauch KL; Runkel LA; Carlson MM; Hronowski X; Foley SF; Young CN; Cheng W; Hochman PS; Baker DP
Protein Sci; 1999 Sep; 8(9):1867-77. PubMed ID: 10493588
[TBL] [Abstract][Full Text] [Related]
59. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
[TBL] [Abstract][Full Text] [Related]
60. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]